Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Drug Metabolism and Personalized Therapy

Official journal of the European Society of Pharmacogenomics and Personalised Therapy

Editor-in-Chief: Llerena, Adrián

Editorial Board: Benjeddou, Mongi / Chen, Bing / Dahl, Marja-Liisa / Devinsky, Ferdinand / Hirata, Rosario / Hubacek, Jaroslav A. / Ingelman-Sundberg, Magnus / Maitland-van der Zee, Anke-Hilse / Manolopoulos, Vangelis G. / Marc, Janja / Melichar, Bohuslav / Meyer, Urs A. / Nair, Sujit / Nofziger, Charity / Peiro, Ana / Sadee, Wolfgang / Salazar, Luis A. / Simmaco, Maurizio / Turpeinen, Miia / Schaik, Ron / Shin, Jae-Gook / Visvikis-Siest, Sophie / Zanger, Ulrich M.


CiteScore 2017: 1.46

SCImago Journal Rank (SJR) 2017: 0.531
Source Normalized Impact per Paper (SNIP) 2017: 0.645

Online
ISSN
2363-8915
See all formats and pricing
More options …
Volume 33, Issue 4

Issues

Volume 34 (2019)

Personalized medicine into health national services: barriers and potentialities

Ana E. Rodríguez Vicente
  • Institute of Molecular and Cellular Biology of Cancer (IBMCC), University of Salamanca-USAL-CSIC, University Hospital of Salamanca, Salamanca, Spain
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Maria José Herrero Cervera
  • Pharmacology Department, Faculty of Medicine, Universidad Valencia and Instituto Investigación Sanitaria La Fe, Valencia, Spain
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ María Luisa Bernal
  • Department of Pharmacology and Physiology, Faculty of Medicine, University of Zaragoza, Zaragoza, Spain
  • Aragon Health Research Institute, Zaragoza, Spain
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Luis Rojas
  • Department of Internal Medicine, Pharmacology and Toxicology Unit, Faculty of Medicine, Pontificia Universidad Catolica de Chile, Santiago, Chile
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Ana M. Peiró
  • Corresponding author
  • Neuropharmacology on Pain (NED) Research Group, Clinical Pharmacology Unit, Department of Health of Alicante – General Hospital, ISABIAL, c/ Pintor Baeza, 12, 03010 Alicante, Spain
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
Published Online: 2018-11-03 | DOI: https://doi.org/10.1515/dmpt-2018-0017

Abstract

Research and innovation in personalized medicine (PM) are extensive and expanding, with several pharmacogenetic/pharmacogenomic (PGx) testing options currently available for a wide range of health problems. However, PGx-guided therapy faces many barriers to full integration into clinical practice and acceptance by practitioner/patient: utilization and uptake by payers in real-world practice are being discussed, and the criteria to guide clinicians and policy makers in PGx test selection are not fully incorporated. This review focuses on the advances of pharmacogenomics to individualize treatments, the relationship between pharmacogenetics and pharmacometabolomics, the new paradigm of the Big Data, the needs and barriers facing PGx clinical application and the situation of PGx testing in health national services. It is based on lectures presented by speakers of the European Society of Pharmacogenomics and Personalised Therapy (ESPT) Fourth Conference, held in Catania, October 4th, 2017.

Keywords: barriers; personalized medicine; pharmacogenetic; potentialities

References

  • 1.

    Evans JP, Meslin EM, Marteau TM, Caulfield T. Genomics. Deflating the genomic bubble. Science 2011;331:861–62.CrossrefPubMedGoogle Scholar

  • 2.

    Jain KK. Personalized medicine. Curr Opin Mol Ther 2002;4: 548–58.PubMedGoogle Scholar

  • 3.

    Katsnelson A. Momentum grows to make ‘personalized’ medicine more ‘precise’. Nat Med 2013;19:249.PubMedCrossrefWeb of ScienceGoogle Scholar

  • 4.

    Manolio TA, Chisholm RL, Ozenberger B, Roden DM, Williams MS, Wilson R, et al. Implementing genomic medicine in the clinic: the future is here. Genet Med 2013;15:258–67.Web of ScienceCrossrefPubMedGoogle Scholar

  • 5.

    Beger RD, Dunn W, Schmidt MA, Gross SS, Kirwan JA, Cascante M, et al. Metabolomics enables precision medicine. “A white paper, community perspective”. Metabolomics 2016;12:1–15.Web of ScienceGoogle Scholar

  • 6.

    Ji Y, Biernacka JM, Hebbring S, Chai Y, Jenkins GD, Batzler A, et al. Pharmacogenomics of selective serotonin reuptake inhibitor treatment for major depressive disorder: genome-wide associations and functional genomics. Pharmacogenomics J 2013;13:456–63.PubMedWeb of ScienceCrossrefGoogle Scholar

  • 7.

    Lorenzo-Tejedor M, De la Cámara C, Lópe-Antón R, Bailon R, Aguiló J, Bernal-Ruiz ML. Direct infusion electrospray mass spectrometry as a new non-invasive tool for serum metabolomics in induced-stress subjects. Eur J Psychiat 2015;29:259–75.CrossrefGoogle Scholar

  • 8.

    Yerges-Armstrong LM, Ellero-Simatos S, Georgiades A, Zhu H, Lewis JP, Horenstein RB, et al. Purine pathway implicated in mechanism of resistance to aspirin therapy: pharmacometabolomics-informed pharmacogenomics. Clin Pharmacol Ther 2013;94:525–32.PubMedWeb of ScienceCrossrefGoogle Scholar

  • 9.

    Rohrer Vitek CR, Abul-Husn NS, Connolly JJ, Hartzler AL, Kitchner T, Peterson JF, et al. Healthcare provider education to support integration of pharmacogenomics in practice: the eMERGE Network experience. Pharmacogenomics 2017;18: 1013–25.Web of SciencePubMedCrossrefGoogle Scholar

  • 10.

    Martin-Sanchez F, Verspoor K. Big data in medicine is driving big changes. Yearb Med Inform 2014;9:14–20.PubMedGoogle Scholar

  • 11.

    Dubois N, Garnier N, Meune C. Potential of big data analytics in the French in vitro diagnostics market. Ann Biol Clin (Paris) 2017;75:683–5.PubMedWeb of ScienceGoogle Scholar

  • 12.

    Varmus H. Ten years on--the human genome and medicine. N Engl J Med 2010;362:2028–9.PubMedCrossrefWeb of ScienceGoogle Scholar

  • 13.

    Mikat-Stevens NA, Larson IA, Tarini BA. Primary-care providers’ perceived barriers to integration of genetics services: a systematic review of the literature. Genet Med 2015;17:169–76.CrossrefPubMedWeb of ScienceGoogle Scholar

  • 14.

    Filipski KK, Murphy JD, Helzlsouer KJ. Updating the landscape of direct-to-consumer. Pharmagenomics Pers Med 2017;10: 229–32.Google Scholar

  • 15.

    Schoretsanitis G, Paulzen M, Unterecker S, Schwarz M, Conca A, Zernig G, et al. TDM in psychiatry and neurology: a comprehensive summary of the consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology, update 2017; a tool for clinicians. World J Biol Psychiatry 2018;19:162–74.CrossrefWeb of ScienceGoogle Scholar

About the article

Corresponding author: Dr. Ana M. Peiró, Neuropharmacology on Pain (NED) Research Group, Clinical Pharmacology Unit, Department of Health of Alicante – General Hospital, ISABIAL, c/ Pintor Baeza, 12, 03010 Alicante, Spain, Phone: +34-96-591-3868

aAna E. Rodríguez Vicente, Maria José Herrero Cervera, María Luisa Bernal, Luis Rojas and Ana M. Peiró contributed equally to this work.


Received: 2018-06-21

Accepted: 2018-10-03

Published Online: 2018-11-03

Published in Print: 2018-12-19


Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

Research funding: None declared.

Employment or leadership: None declared.

Honorarium: None declared.

Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.


Citation Information: Drug Metabolism and Personalized Therapy, Volume 33, Issue 4, Pages 159–163, ISSN (Online) 2363-8915, ISSN (Print) 2363-8907, DOI: https://doi.org/10.1515/dmpt-2018-0017.

Export Citation

©2018 Walter de Gruyter GmbH, Berlin/Boston.Get Permission

Comments (0)

Please log in or register to comment.
Log in